keyword
MENU ▼
Read by QxMD icon Read
search

Breast cancer her2+ recurrence

keyword
https://www.readbyqxmd.com/read/28430808/quantification-of-hypoxia-related-gene-expression-as-a-potential-approach-for-clinical-outcome-prediction-in-breast-cancer
#1
Abderrahim El Guerrab, Anne Cayre, Fabrice Kwiatkowski, Maud Privat, Jean-Marc Rossignol, Fabrice Rossignol, Frédérique Penault-Llorca, Yves-Jean Bignon
Breast cancers are solid tumors frequently characterized by regions with low oxygen concentrations. Cellular adaptations to hypoxia are mainly determined by "hypoxia inducible factors" that mediate transcriptional modifications involved in drug resistance and tumor progression leading to metastasis and relapse occurrence. In this study, we investigated the prognostic value of hypoxia-related gene expression in breast cancer. A systematic review was conducted to select a set of 45 genes involved in hypoxia signaling pathways and breast tumor progression...
2017: PloS One
https://www.readbyqxmd.com/read/28428277/immune-gene-expression-is-associated-with-genomic-aberrations-in-breast-cancer
#2
Anton Safonov, Tingting Jiang, Giampaolo Bianchini, Balázs Győrffy, Thomas Karn, Christos Hatzis, Lajos Pusztai
The presence of tumor-infiltrating lymphocytes (TIL) is a favorable prognostic factor in breast cancer, but what drives immune infiltration remains unknown. Here we examine if clonal heterogeneity, total mutation load, neoantigen load, copy number variations (CNV), gene- or pathway-level somatic mutations, or germline polymorphisms (SNP) are associated with immune metagene expression in breast cancer subtypes. Thirteen published immune metagenes correlated separately with genomic metrics in the 3 major breast cancer subtypes...
April 20, 2017: Cancer Research
https://www.readbyqxmd.com/read/28421181/mct1-in-invasive-ductal-carcinoma-monocarboxylate-metabolism-and-aggressive-breast-cancer
#3
Jennifer M Johnson, Paolo Cotzia, Roberto Fratamico, Lekha Mikkilineni, Jason Chen, Daniele Colombo, Mehri Mollaee, Diana Whitaker-Menezes, Marina Domingo-Vidal, Zhao Lin, Tingting Zhan, Madalina Tuluc, Juan Palazzo, Ruth C Birbe, Ubaldo E Martinez-Outschoorn
Introduction: Monocarboxylate transporter 1 (MCT1) is an importer of monocarboxylates such as lactate and pyruvate and a marker of mitochondrial metabolism. MCT1 is highly expressed in a subgroup of cancer cells to allow for catabolite uptake from the tumor microenvironment to support mitochondrial metabolism. We studied the protein expression of MCT1 in a broad group of breast invasive ductal carcinoma specimens to determine its association with breast cancer subtypes and outcomes. Methods: MCT1 expression was evaluated by immunohistochemistry on tissue micro-arrays (TMA) obtained through our tumor bank...
2017: Frontiers in Cell and Developmental Biology
https://www.readbyqxmd.com/read/28419166/comparison-of-standardized-uptake-value-of-18f-fdg-pet-ct-with-21-gene-recurrence-score-in-estrogen-receptor-positive-her2-negative-breast-cancer
#4
Sung Gwe Ahn, Jae-Hoon Lee, Hak Woo Lee, Tae Joo Jeon, Young Hoon Ryu, Kun Min Kim, Joohyuk Sohn, Mijin Yun, Seung Ah Lee, Joon Jeong, Seung Il Kim
BACKGROUND: We investigated the relationship between 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG-PET-CT) standardized uptake value (SUV) and 21-gene recurrence score (RS) in estrogen receptor (ER)-positive/HER2-negative breast cancer. MATERIALS AND METHODS: One hundred sixty-seven patients were identified among those who underwent preoperative 18F-FDG-PET-CT and had RS. Maximum SUV was obtained from 18F-FDG-PET-CT; the cut-off point was 4...
2017: PloS One
https://www.readbyqxmd.com/read/28418843/cd24-expression-and-differential-resistance-to-chemotherapy-in-triple-negative-breast-cancer
#5
Xinyu Deng, Sophia Apple, Hong Zhao, Jeongyoon Song, Minna Lee, William Luo, Xiancheng Wu, Debra Chung, Richard J Pietras, Helena R Chang
Breast cancer (BC) is a leading cause of cancer-related death in women. Adjuvant systemic chemotherapies are effective in reducing risks of recurrence and have contributed to reduced BC mortality. Although targeted adjuvant treatments determined by biomarkers for endocrine and HER2-directed therapies are largely successful, predicting clinical benefit from chemotherapy is more challenging. Drug resistance is a major reason for treatment failures. Efforts are ongoing to find biomarkers to select patients most likely to benefit from chemotherapy...
March 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28412963/posttranslationally-modified-progesterone-receptors-direct-ligand-specific-expression-of-breast-cancer-stem-cell-associated-gene-programs
#6
Todd P Knutson, Thu H Truong, Shihong Ma, Nicholas J Brady, Megan E Sullivan, Ganesh Raj, Kathryn L Schwertfeger, Carol A Lange
BACKGROUND: Estrogen and progesterone are potent breast mitogens. In addition to steroid hormones, multiple signaling pathways input to estrogen receptor (ER) and progesterone receptor (PR) actions via posttranslational events. Protein kinases commonly activated in breast cancers phosphorylate steroid hormone receptors (SRs) and profoundly impact their activities. METHODS: To better understand the role of modified PRs in breast cancer, we measured total and phospho-Ser294 PRs in 209 human breast tumors represented on 2754 individual tissue spots within a tissue microarray and assayed the regulation of this site in human tumor explants cultured ex vivo...
April 17, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28410290/diagnostic-and-prognostic-impact-of-fluorine-18-fluorodeoxyglucose-pet-ct-in-preoperative-and-postoperative-setting-of-breast-cancer-patients
#7
Laura Evangelista, Anna R Cervino, Silvia Michieletto, Tania Saibene, Cristina Ghiotto, Valentina Guarneri, Pierfranco Conte, Pasquale Reccia, Giorgio Saladini
PURPOSE: The aim of this study was to assess the diagnostic and prognostic value of fluorine-18-fluorodeoxyglucose (F-FDG) PET/CT in patients with breast cancer (BC) in the preoperative and the postoperative setting. PATIENTS AND METHODS: Between 2011 and 2015, we prospectively enrolled 275 patients (mean age: 53 years) with BC (stage I-III; triple-negative or HER2-positive cancer). One-hundred and forty-nine (54.2%) patients underwent F-FDG PET/CT before neoadjuvant therapy and 126 (45...
April 13, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28409323/differences-in-subtype-distribution-between-screen-detected-and-symptomatic-invasive-breast-cancer-and-their-impact-on-survival
#8
N Kobayashi, M Hikichi, K Ushimado, A Sugioka, Y Kiriyama, M Kuroda, T Utsumi
PURPOSE: Stage shift is considered a major reason for more favorable outcomes in patients with screen-detected breast cancer. However, even after adjusting for clinical stage, unresolved issues concerning the reasons for a survival benefit associated with screening programs remain. This study aims to evaluate differences in subtype distribution and outcomes among patients with screen-detected and symptomatic invasive breast cancer and assess whether variations in subtype distribution could explain differences in prognosis...
April 13, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28407750/adjuvant-treatment-recommendations-for-patients-with-er-positive-her2-negative-early-breast-cancer-by-swiss-tumor-boards-using-the-21-gene-recurrence-score-sakk-26-10
#9
Bernhard C Pestalozzi, Christoph Tausch, Konstantin J Dedes, Christoph Rochlitz, Stefan Zimmermann, Roger von Moos, Ralph Winterhalder, Thomas Ruhstaller, Andreas Mueller, Katharina Buser, Markus Borner, Urban Novak, Catrina Uhlmann Nussbaum, Bettina Seifert, Martin Bigler, Vincent Bize, Simona Berardi Vilei, Christoph Rageth, Stefan Aebi
BACKGROUND: To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ODX) on treatment recommendations by Swiss multidisciplinary tumor boards (TB). METHODS: SAKK 26/10 is a multicenter, prospective cohort study of early breast cancer patients: Eligibility: R0-resection, ≥10% ER+ malignant cells, HER2-, pN0/pN1a. Patients were stratified into low-risk (LR) and non-low-risk (NLR) groups based on involved nodes (0 vs 1-3) and five additional predefined risk factors...
April 13, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28407247/using-the-21-gene-assay-from-core-needle-biopsies-to-choose-neoadjuvant-therapy-for-breast-cancer-a-multicenter-trial
#10
Harry D Bear, Wen Wan, André Robidoux, Peter Rubin, Steven Limentani, Richard L White, James Granfortuna, Judith O Hopkins, Dwight Oldham, Angel Rodriguez, Amy P Sing
OBJECTIVE: We hypothesized that the Oncotype Dx(®) 21-gene Recurrence Score (RS) could guide neoadjuvant systemic therapy (NST) to facilitate breast conserving surgery (BCS) for hormone receptor positive (HR+) breast cancers. METHODS: This study enrolled patients with HR+, HER2-negative, invasive breast cancers not suitable for BCS (size ≥ 2 cm). Core needle biopsy blocks were tested. For tumors with RS < 11, patients received hormonal therapy (NHT); patients with RS > 25 tumors received chemotherapy (NCT); patients with RS 11-25 were randomized to NHT or NCT...
April 13, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28404972/distribution-patterns-of-21-gene-recurrence-score-in-980-chinese-estrogen-receptor-positive-her2-negative-early-breast-cancer-patients
#11
Wu Jiayi, Fang Yan, Lin Lin, Fei Xiaochun, Gao Weiqi, Zhu Siji, Zong Yu, Chen Xiaosong, Huang Ou, He Jianrong, Zhu Li, Chen Weiguo, Li Yafen, Shen Kunwei
AIM: The current study aimed to explore the distribution patterns of 21-gene recurrence score (RS) assay in Chinese early breast cancer patients. METHODS: Nine hundred and eighty consecutive estrogen receptor(ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer patients treated at Ruijin Hospital, Shanghai Jiaotong University, School of Medicine from 2009 to 2016 were retrospectively recruited. Reverse transcriptase-polymerase chain reaction (RT-PCR) assay of 21 genes were conducted in paraffin-embedded tumor tissue to calculate the RS...
March 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28401365/discerning-the-clinical-relevance-of-biomarkers-in-early-stage-breast-cancer
#12
Tarah J Ballinger, Nawal Kassem, Fei Shen, Guanglong Jiang, Mary Lou Smith, Elda Railey, John Howell, Carol B White, Bryan P Schneider
PURPOSE: Prior data suggest that breast cancer patients accept significant toxicity for small benefit. It is unclear whether personalized estimations of risk or benefit likelihood that could be provided by biomarkers alter treatment decisions in the curative setting. METHODS: A choice-based conjoint (CBC) survey was conducted in 417 HER2-negative breast cancer patients who received chemotherapy in the curative setting. The survey presented pairs of treatment choices derived from common taxane- and anthracycline-based regimens, varying in degree of benefit by risk of recurrence and in toxicity profile, including peripheral neuropathy (PN) and congestive heart failure (CHF)...
April 11, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28378298/differential-impact-of-hormone-receptor-status-on-survival-and-recurrence-for-her2-receptor-positive-breast-cancers-treated-with-trastuzumab
#13
Andrew McGuire, Olga Kalinina, Emma Holian, Catherine Curran, Carmel A Malone, Ray McLaughlin, Aoife Lowery, James A L Brown, Michael J Kerin
INTRODUCTION: Hormone receptor status has major implications for treatment and survival of breast cancer. Yet the impact of hormone receptor status on outcome after Trastuzumab has received little attention. The objective here was to explore any differential effects of Trastuzumab treatment (Trast +ve) on Luminal B HER2 or HER2+(ER-) breast cancer subtypes. METHODS: A cohort of 469 HER2 receptor-positive breast cancers was categorised by molecular subtype and Trastuzumab treatment...
April 4, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28378258/erratum-to-post-relapse-survival-in-patients-with-the-early-and-late-distant-recurrence-in-estrogen-receptor-positive-her2-negative-breast-cancer
#14
Akiko Ogiya, Kieko Yamazaki, Rie Horii, Tadahiko Shien, Yoshiya Horimoto, Norikazu Masuda, Touko Inao, Mitsuchika Hosoda, Naoko Ishida, Tomofumi Osako, Masato Takahashi, Yumi Endo, Yuichiro Miyoshi, Hiroyuki Yasojima, Nobumoto Tomioka, Hiroko Yamashita
No abstract text is available yet for this article.
April 4, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28376188/regional-nodal-irradiation-after-breast-conserving-surgery-for-early-her2-positive-breast-cancer-results-of-a-subanalysis-from-the-altto-trial
#15
Isabelle Gingras, Eileen Holmes, Evandro De Azambuja, David H A Nguyen, Miguel Izquierdo, Jo Anne Zujewski, Moshe Inbar, Bjorn Naume, Gianluca Tomasello, Julie R Gralow, Antonio C Wolff, Lyndsay Harris, Michael Gnant, Alvaro Moreno-Aspitia, Martine J Piccart, Hatem A Azim
Background: Two randomized trials recently demonstrated that regional nodal irradiation (RNI) could reduce the risk of recurrence in early breast cancer; however, these trials were conducted in the pretrastuzumab era. Whether these results are applicable to human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients treated with anti-HER2-targeted therapy is unknown. Methods: This retrospective analysis was performed on patients with node-positive breast cancer who were enrolled in the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization phase III adjuvant trial and subjected to BCS...
August 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28359319/endocrine-therapy-initiation-discontinuation-and-adherence-and-breast-imaging-among-21-gene-recurrence-score-assay-eligible-women-under-age-65
#16
Suzanne C O'Neill, Claudine Isaacs, Filipa Lynce, Deena Mary Atieh Graham, Calvin Chao, Vanessa B Sheppard, Yingjun Zhou, Chunfu Liu, Nandini Selvam, Marc D Schwartz, Arnold L Potosky
BACKGROUND: Aside from chemotherapy utilization, limited data are available on the relationship between gene expression profiling (GEP) testing and breast cancer care. We assessed the relationship between GEP testing and additional variables and the outcomes of endocrine therapy initiation, discontinuation and adherence, and breast imaging exams in women under age 65 years. METHODS: Data from five state cancer registries were linked with claims data and GEP results...
March 31, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/28356770/breast-cancer-in-patients-with-li-fraumeni-syndrome-a-case-series-study-and-review-of-literature
#17
Amara G Nandikolla, Sangeetha Venugopal, Jesus Anampa
BACKGROUND: Li-Fraumeni Syndrome (LFS) is a rare disease with autosomal dominant inheritance linked to germline mutations of tumor suppressor gene TP53. These patients are predisposed to malignancies such as sarcoma, breast cancer, leukemia, and other malignancies. Breast cancer, the most common malignancy in adult patients with LFS, has an early-onset presentation and is usually treated as per the guidelines for the general population due to the limited literature about breast cancer in LFS...
2017: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28350001/a-new-molecular-prognostic-score-for-predicting-the-risk-of-distant-metastasis-in-patients-with-hr-her2-early-breast-cancer
#18
Gyungyub Gong, Mi Jeong Kwon, Jinil Han, Hee Jin Lee, Se Kyung Lee, Jeong Eon Lee, Seon-Heui Lee, Sarah Park, Jong-Sun Choi, Soo Youn Cho, Sei Hyun Ahn, Jong Won Lee, Sang Rae Cho, Youngho Moon, Byung-Ho Nam, Seok Jin Nam, Yoon-La Choi, Young Kee Shin
To make an optimal treatment decision for early stage breast cancer, it is important to identify risk of recurrence. Here, we developed and validated a new prognostic model for predicting the risk of distant metastasis in patients with pN0-N1, hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer treated with hormone therapy alone. RNA was extracted from formalin-fixed, paraffin-embedded tumor tissues and gene expression was measured by quantitative real-time reverse transcription-PCR. The relative expression of six novel prognostic genes was combined with two clinical variables (nodal status and tumor size) to calculate a risk score (BCT score)...
March 28, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28347625/combination-of-radiotherapy-and-double-blockade-her2-with-pertuzumab-and-trastuzumab-for-her2-positive-metastatic-or-locally-recurrent-unresectable-and-or-metastatic-breast-cancer-assessment-of-early-toxicity
#19
Z Ajgal, S de Percin, V Diéras, J Y Pierga, F Campana, A Fourquet, Y M Kirova
BACKGROUND AND PURPOSES: We evaluate the early toxicity of concurrent use of radiotherapy, pertuzumab and trastuzumab in patients with HER2-positive metastatic or locally recurrent unresectable breast cancer. PATIENTS AND METHODS: A retrospective study was performed in a population of 23 consecutive patients between 2013 and 2015. Radiotherapy was performed on the chest area or metastatic sites during maintenance with pertuzumab and trastuzumab after six cycles of pertuzumab, trastuzumab and docetaxel...
March 24, 2017: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/28334900/cdk12-regulates-alternative-last-exon-mrna-splicing-and-promotes-breast-cancer-cell-invasion
#20
Jerry F Tien, Alborz Mazloomian, S-W Grace Cheng, Christopher S Hughes, Christalle C T Chow, Leanna T Canapi, Arusha Oloumi, Genny Trigo-Gonzalez, Ali Bashashati, James Xu, Vicky C-D Chang, Sohrab P Shah, Samuel Aparicio, Gregg B Morin
CDK12 (cyclin-dependent kinase 12) is a regulatory kinase with evolutionarily conserved roles in modulating transcription elongation. Recent tumor genome studies of breast and ovarian cancers highlighted recurrent CDK12 mutations, which have been shown to disrupt DNA repair in cell-based assays. In breast cancers, CDK12 is also frequently co-amplified with the HER2 (ERBB2) oncogene. The mechanisms underlying functions of CDK12 in general and in cancer remain poorly defined. Based on global analysis of mRNA transcripts in normal and breast cancer cell lines with and without CDK12 amplification, we demonstrate that CDK12 primarily regulates alternative last exon (ALE) splicing, a specialized subtype of alternative mRNA splicing, that is both gene- and cell type-specific...
March 17, 2017: Nucleic Acids Research
keyword
keyword
115348
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"